|

Mesothelioma Can Strike Younger Patients Without Known Risks

10141315_woman1

Mesothelioma is a cancer that typically affects middle-aged or older men who were exposed to asbestos on the job. But even younger patients with no known history of asbestos exposure may develop mesothelioma, and should be evaluated if they have signs of the disease, according to a recent review in the West Virginia Medical Journal. Even when mesothelioma is properly diagnosed, treatment options remain limited and the prognosis is usually grim, the authors say.

The review presented the case of a 38-year-old, otherwise healthy woman who developed shortness of breath and chest pain, which worsened over time. Pathology tests revealed cancerous cells that are typical of mesothelioma, even though the woman had no apparent risks for the disease. “The family denied any known history of asbestos exposure, either in her or other family members,” says lead study author Carol Montjoy, MD, Fellow in the West Virginia University Section of Pulmonary/CCM.

Dr. Montjoy and her colleagues say this case illustrates the need to consider a diagnosis of mesothelioma in patients who have a growth in the pleura (the lining of the chest and lungs), even if they don’t fit the typical profile of a mesothelioma patient.

Even with the best techniques available today, mesothelioma remains an elusive cancer—difficult to detect, and challenging to treat. X-ray and computed tomography (CT) scans can identify growths in the pleura, but when tissue samples are examined, mesothelioma is difficult to distinguish from adenocarcinoma (a type of cancer that begins in glandular tissue). The use of immunohistochemical stains—a technique that stains cancer cells to identify biological markers for cancer—has helped doctors more accurately diagnose mesothelioma, but once this cancer has been identified, there is often little doctors can do to attack it.

“Mesothelioma, unfortunately, is an aggressive tumor with a poor response to multiple common modalities, including surgery, chemotherapy, and radiation treatment,” Dr. Montjoy says. These treatments can only improve survival time by a few months (an untreated mesothelioma patient may live 4-13 months, while a treated patient lives 6-18 months).

Researchers are currently investigating new treatment strategies, which they hope will improve the prognosis for mesothelioma patients. One relatively new treatment option attempts to improve survival by combining therapies. Patients first have radical surgery called extrapleural pneumonectomy (EPP), which removes part of the lung, its lining, the lining of the heart, and the diaphragm. Surgery is followed by a combination of chemotherapy and radiation.

Yet even this aggressive approach does not appear to offer patients much of a benefit. Although one study reported that patients who had this therapy survived an average of 23 months, other research has not produced the same results. “Currently, data is still being collected to determine if outcomes with this approach are any better; so far, most studies indicate that this approach does not offer any substantial benefit,” Dr. Montjoy says. For now, mesothelioma “remains an aggressive tumor with a dismal prognosis,” the authors conclude.

Source:

Montjoy C, Parker J, Petsonk L, Teba L, Fallon K. Mesothelioma Review. West Virginia Medical Journal. 2009;105:13-16.

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…